Identification of the immune response against tumour antigens in patients with lung adenocarcinoma
Completed
- Conditions
- adenocarcinomalung cancer10038666
- Registration Number
- NL-OMON56899
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Patients with suspected or proven lung adenocarcinoma who will undergo endosonograpgy in order to pre-operatively stage the mediastinum for lymph node metastases.
Exclusion Criteria
No adenocarcinoma
No clinical indication for undergoing endosonography
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary objective of this study is<br /><br>- to assess the presence, type and strength of XAGE-1B-specific cellular immune<br /><br>responses of lung cancer patients in the peripheral blood, mediastinal lymph<br /><br>nodes and the primary tumour.<br /><br>- to assess the expression of the XAGE-1B antigen in the primary lung tumor</p><br>
- Secondary Outcome Measures
Name Time Method <p>- the presence, type and strength of XAGE-1B-specific cellular immune response<br /><br>in the primary tumour of patients that undergo tumour resection after<br /><br>diagnostic work-up<br /><br>- the presence, type and strength of antigen-specific cellular immune responses<br /><br>against potential other tumour antigens (including p53 and HPV16) in lung<br /><br>adenocarcinoma patients<br /><br>- whether the presence of a specific cellular immune response is associated<br /><br>with a certain type of lung adenocarcinoma patients.<br /><br>- whether chemotherapy enhances the activation of systemically present<br /><br>antigen-specific immune response.<br /><br>- whether there exists a relation between the presence of a specific immune<br /><br>response and clinical outcome of patients with lung adenocarcinoma</p><br>